Growth hormone improves bone mineral content in children with cystic fibrosis.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Osteoporosis and osteopenia have been reported as common complications of cystic fibrosis (CF); however, little is known about accrual of bone mineral in CF.

The goal of their study was to measure bone mineral content (BMC) in non-acutely-ill, but poorly growing children with CF, and to determine the relationship between height, lean body mass and BMC.

Their second aim was to evaluate the effect of one year of treatment with human recombinant growth hormone (GH) on total body BMC.

Who Took Part

The age groups tagged for this paper are children, both men and women.

The researchers measured total-body BMC using dual energy X-ray absorptiometry in 32 poorly growing (height < or =10th percentile for age) prepubertal Caucasian children (ages 7 years 6 months-12 years 9 months, 17 M and 15, F) with CF.

One half of the children were randomly assigned to receive treatment with GH (GHTX).

How the Study Was Run

The design is described as randomized.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

BMC and lean tissue mass (LTM) were measured at baseline, at 6 months and one year.

Results were compared to reference data maintained for healthy children matched for age and ethnicity.

Sex steroid and IGF-I levels were also measured.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Age Determination by Skeleton, Body Composition, Body Height, Bone Density, Bone Diseases, Metabolic and Cystic Fibrosis.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.